Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

22 trials with published results (14%)

Research Maturity

77 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.0%

11 terminated out of 157 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

26%

41 trials in Phase 3/4

Results Transparency

29%

22 of 77 completed with results

Key Signals

22 with results88% success11 terminated

Data Visualizations

Phase Distribution

98Total
Not Applicable (27)
Early P 1 (2)
P 1 (12)
P 2 (16)
P 3 (6)
P 4 (35)

Trial Status

Completed77
Unknown33
Recruiting22
Terminated11
Not Yet Recruiting7
Withdrawn4

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 77 completed trials

Clinical Trials (157)

Showing 20 of 20 trials
NCT01568697RecruitingPrimary

Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)

NCT02310867Phase 2RecruitingPrimary

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

NCT06262776Not ApplicableRecruitingPrimary

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

NCT05043870Phase 4Recruiting

Combined Immunosuppression for Pediatric Crohn's Disease

NCT06354179Phase 4Recruiting

Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

NCT07479511Active Not Recruiting

Adaptation of Lung Transplant Recipients at Extreme Altitude

NCT00619528Not ApplicableCompletedPrimary

HLA-Identical Sibling Renal Transplant Tolerance

NCT06879106Not ApplicableCompleted

Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation

NCT07204080Phase 2Not Yet Recruiting

(TNX-1500) in Kidney Transplant Recipients

NCT05756036Completed

Torque Teno Virus: A Biomarker of Immunosuppression

NCT01086904Phase 2Completed

Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients

NCT05462561Not ApplicableRecruiting

Vascularized Composite Bladder Allograft Transplantation

NCT07206277Not ApplicableRecruitingPrimary

Fibroscan to Guide Post Transplant Immunosuppression Minimization

NCT05616130Recruiting

Pathological Myeloid Activation After Sepsis and Trauma

NCT07295535Recruiting

Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts

NCT01123187Not ApplicableCompleted

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

NCT06027229Phase 2CompletedPrimary

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

NCT06701825Phase 4Recruiting

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

NCT06271681Phase 4Not Yet Recruiting

Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

NCT05655546Not ApplicableTerminated

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

Scroll to load more

Research Network

Activity Timeline